^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    RUNX3 underexpression

    i
    Other names: RUNX3, Runt related transcription factor 3, AML2, CBFA3, PEBP2aC
    Entrez ID:
    864
    Related biomarkers:
    Expression
    almost4years
    Combined Detection of RUNX3 and EZH2 in Evaluating Efficacy of Neoadjuvant Therapy and Prognostic Value of Middle and Low Locally Advanced Rectal Cancer. (PubMed, Front Oncol)
    All patients received neoadjuvant chemoradiotherapy (long range radiotherapy + oral capecitabine) + total mesorecta excision (TME) surgery...Multivariate survival analysis showed that EZH2 expression and PN were good predictors of 5-year DFS and 5-year OS, whereas RUNX3 was a good predictor of 5-year DFS but not 5-year OS. Expression level of RUNX3 and EZH2 accurately predicts clinical efficacy of neoadjuvant chemoradiotherapy and the prognosis of LARC patients, suggesting that RUNX3 and EZH2 can be used as pivotal clinical predictors for LARC.
    Journal
    |
    EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • TCF3 (Transcription Factor 3) • RUNX3 (RUNX Family Transcription Factor 3) • TRG (T Cell Receptor Gamma Locus)
    |
    RUNX3 underexpression
    |
    capecitabine